FDA Approves Evolence

HERZLIYA, Israel & MORRIS PLAINS, N.J.--(BUSINESS WIRE)--Jun
30, 2008 - The U.S. Food and Drug Administration ("FDA") today
announced the approval of Evolence for the correction of
moderate to deep facial wrinkles and folds, such as nasolabial
folds. Evolence is a new advanced collagen-based structural
dermal filler, and a first of its kind product. The introduction of
Evolence marks the first dermal filler entry for the Aesthetics
Group of OrthoNeutrogena. While new to the United States,
Evolence has been available in other markets such as in Canada,
Western and Eastern Europe, Israel, South Korea and Russia since
2004.

"Evolence represents a new generation of facial fillers, an
innovative structural agent providing beautiful, immediate results
by replacing the collagen lost with long-lasting, naturally sourced
collagen," said Annie Heremans, M.D., Ph.D., Vice President,
responsible for the Company's research and development of the
Medical and Aesthetic Dermatology franchises. "We are pleased to
enter the U.S. aesthetic space with a differentiated dermal filler
designed for optimal patient outcomes. Given our rich heritage in
skin care and commitment to science, we anticipate Evolence will
be a welcome addition to current aesthetic treatment options."

Evolence will be introduced throughout the second half of
2008, in coordination with physician training, to ensure optimal
patient satisfaction and outcomes.

Evolence represents a breakthrough in aesthetics. As one of
nature's most fundamental and abundant building blocks, collagen
comprises up to 80% of the dermis and it helps maintain skin
strength, structure and support. Collagen naturally breaks down as
a person ages, leading to the appearance of wrinkles, lines and
folds.

Evolence, and its proprietary Glymatrix Technology, uses
naturally sourced collagen to replace the body's lost collagen,
adding volume and structural support in depleted areas, for a more
naturally youthful appearance. In addition, no pre-test is needed,
and Glymatrix Technology delivers longer-lasting durability
than previous collagen dermal fillers.

Results are visible and immediate at the time of treatment, with
minimal to no bruising or swelling, allowing physician and patient
to gauge the amount of wrinkle correction with more precision.
Evolence is recommended for the correction of moderate to deep
facial wrinkles and folds, such as nasolabial folds, to be injected
in the mid-to-deep dermis.

"We now have a collagen filler that does not require a pre-test
and delivers immediate, beautiful and natural-looking results that
last with minimal to little downtime for the patient," said Z. Paul
Lorenc, M.D., F.A.C.S., Assistant Professor of Surgery, New York
University School of Medicine and Principal Investigator on the
Evolence U.S. pivotal study. "Evolence provides consistent
and predictable results for all patients with every treatment."

About Evolence

Evolence is an advanced collagen-based structural dermal
filler that provides long-lasting treatment of moderate to deep
facial wrinkles and folds, such as nasolabial folds. The results of
treatment with Evolence are immediate, with little to no
downtime post-treatment and clinically proven to last through six
months. Additional data for 12-month duration approval is being
filed with the FDA.

Unlike other dermal fillers that use hyaluronic acid (HA), which
absorb water to create their effect, Evolence is a true
structural agent due to its three-dimensional collagen matrix. This
collagen structure benefits patients as it is directly linked to
the minimal bruising and swelling that might result. Evolence
does not use chemicals for cross-linking like many other products
do, but instead uses natural sugar to improve durability.
Evolence collagen is cross-linked through its patented
Glymatrix Technology using the natural sugar, D-Ribose. The
Glymatrix process is designed to:

The naturally sourced porcine collagen used in Evolence is
the most genetically similar to human collagen and has been used
safely and effectively for decades in various medical applications,
including heart valve replacement.

This new generation collagen filler is intended for injection
into the mid-to-deep dermis for the correction of moderate to deep
facial wrinkles and folds, such as nasolabial folds. The most
common side effects of Evolence injections are usually
injection-site related and include mild swelling, redness, and
pain. Other rare side effects include the development of small
areas of firmness under the skin at the treated sites that may be
noticed when the areas are pressed upon.

Evolence has undergone rigorous testing and has been
demonstrated to be safe and effective through clinical studies. For
more information on the product, visit www.evolence.com.

About OrthoNeutrogena, Aesthetics Group

Evolence is marketed in the United States by the Aesthetics
Group of OrthoNeutrogena, a division of Ortho-McNeil-Janssen
Pharmaceuticals, Inc., and part of the Johnson & Johnson family
of companies. This innovative collagen structural dermal filler was
developed by ColBar LifeScience, Ltd., a biotechnology company
specializing in reconstructive medicine and tissue engineering. The
company has perfected a technique in which collagen, a main
building block of living organisms, can be purified and transformed
so as to create a variety of products that are structurally stable
and safe for medical applications. ColBar LifeScience Ltd., is also
subsidiary of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

(This press release contains "forward-looking statements" as
defined in the Private Securities Litigation Reform Act of 1995.
These statements are based on current expectations of future
events. If underlying assumptions prove inaccurate or unknown risks
or uncertainties materialize, actual results could vary materially
from the Company's expectations and projections. Risks and
uncertainties include general industry conditions and competition;
economic conditions, such as interest rate and currency exchange
rate fluctuations; technological advances and patents attained by
competitors; challenges inherent in new product development,
including obtaining regulatory approvals; domestic and foreign
health care reforms and governmental laws and regulations; and
trends toward health care cost containment. A further list and
description of these risks, uncertainties and other factors can be
found in Exhibit 99 of Johnson & Johnson's Annual Report on
Form 10-K for the fiscal year ended December 30, 2007. Copies of
this Form 10-K, as well as subsequent filings, are available online
at www.sec.gov, www.jnj.com or on request from Johnson &
Johnson. The Company does not undertake to update any
forward-looking statements as a result of new information or future
events or developments.)

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.